Northwire Canada EditionFriday, October 16, 2026
Northwire
⌕
GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8% GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8%
Financings

Restart Life Receives Aggregate Gross Proceeds of Approximately $590,000 from Warrant Exercises and Loan

HEAL · Price

Executive Summary

  • Restart Life Sciences Corp. raised approximately CAD $590,000 through warrant exercises ($340k) and a CAD $250,000 loan.
  • The proceeds are earmarked to fund the planned acquisition of 100% of Holy Crap Foods Inc. and for general working capital.
  • The loan carries a 12% annual interest rate, 12‑month term, with a renewal option; warrant exercises included a $130,000 contribution from the CEO.

Key Details

  • Warrant Exercises: Holders exercised 4,103,023 warrants generating ~CAD $340,000 gross proceeds.
  • CEO Participation: The CEO exercised 1,303,023 warrants for ~CAD $130,000 of the total.
  • Loan Financing: Arm’s‑length loan of CAD $250,000 principal; 12% per annum interest payable monthly; 12‑month term with optional renewal upon mutual agreement.
  • Use of Proceeds: Net proceeds will be applied to:
  • Advance a binding Letter of Intent (dated Dec 22 2025) to acquire 100% of Holy Crap Foods Inc. from Happy Belly Food Group (CSE: HBFG).
  • Support ongoing Food Studies initiatives.
  • Provide general working capital.
  • Acquisition Conditions: Completion subject to satisfactory due diligence, execution of a definitive agreement, and regulatory approvals including CSE consent.
  • Forward‑Looking Statements: The release contains forward‑looking information regarding loan repayment, use of proceeds, and acquisition completion; risks and uncertainties are disclosed.

Notable Quotes

  • “Restart Life Sciences extends its appreciation to shareholders for their continued support as the Company advances its mission and executes on its strategic growth initiatives.” – Steve Loutskou, CEO.
Read the original news release →

More from Restart Life Sciences Corp.